Clinical Trials

Great Falls Clinic Open Research Studies

Learn more about Great Falls Clinic’s Clinical Research Department.

AMG 145: Phase III


Treating: Cardiac
Indication: Dyslipidemia
Status: Not Currently Enrolling

A double blind, randomized, placebo-controlled, multicenter study assessing the impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease

ATB200-02: Phase I/II


Treating: Pompe Disease
Indication: Pompe Disease
Status: Open/Currently Not Enrolling
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-administered With Oral AT2221 in Adult Subjects With Pompe Disease

CAIN457H2315: Phase III


Treating: Axial Spondyloarthritis
Indication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Enrolling

A randomized, double-blind, placebo-controlled multicenter
study of secukinumab to evaluate the safety, tolerability
and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis

CIRT: Cardiovascular Inflammation Reduction Trial


Treating: Cardiac
Status: Open and Currently Enrolling

A randomized, double-blind placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.

CLEE011A2404: Phase IIIb


Treating: Advanced Breast Cancer
Indication: Hormone Receptor-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer
Status: Open and Currently Enrolling
COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

D1699C00001: Phase III


Treating: Heart Failure
Indication: Chronic Heart Failure with Reduced Ejection Fraction
Status: Open/Currently Enrolling
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction

DECLARE: Phase IIIb

Treating: Cardiac

Treating: Cardiac
Status: Not Currently Enrolling

A multicenter, randomized, double blind, placebo-controlled trial to evaluate the effect of Dapagliflozin 10mg once daily on the incidence of cardiovascular death, myocardial infarction or ischemic stroke in patients with type 2 diabetes.

DIV-SCLC-301: Phase II/III


Treating: Lung Cancer
Indication: Small Cell Lung Cancer
Status: Open/Currently Enrolling

A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

Novartis: Phase IV


Treating: Acromegaly
Status: Open and Currently Enrolling

A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing’s Disease or Acromegaly.

Meet Our Providers

Kenneth D. Evans, AuD

Audiology

Otolaryngology

Brian Thomas, MD

Ambulatory Surgery Center

Otolaryngology

Andrew Lindekugel, DPM

Ambulatory Surgery Center

Podiatry / Podiatric Surgery